Synthesis monoclonal antibodies

Product formation kinetics in mammalian cells has been studied extensively for hybridomas. Most monoclonal antibodies are produced at an enhanced rate during the Gq phase of the cell cycle (8—10). A model for antibody production based on this cell cycle dependence and traditional Monod kinetics for cell growth has been proposed (11). However, it is not clear if this cell cycle dependence carries over to recombinant CHO cells. In fact it has been reported that dihydrofolate reductase, the gene for which is co-amplified with the gene for the recombinant protein in CHO cells, synthesis is associated with the S phase of the cell cycle (12). Hence it is possible that the product formation kinetics in recombinant CHO cells is different from that of hybridomas. 

Mammalian Cells Unlike microbial cells, mammalian cells do not continue to reproduce forever. Cancerous cells have lost this natural timing that leads to death after a few dozen generations and continue to multiply indefinitely. Hybridoma cells from the fusion of two mammalian lymphoid cells, one cancerous and the other normal, are important for mammalian cell culture. They produce monoclonal antibodies for research, for affinity methods for biological separations, and for analyses used in the diagnosis and treatment of some diseases. However, the frequency of fusion is low. If the unfused cells are not killed, the myelomas 1 overgrow the hybrid cells. The myelomas can be isolated when there is a defect in their production of enzymes involved in nucleotide synthesis. Mammahan cells can produce the necessary enzymes and thus so can the fused cells. When the cells are placed in a medium in which the enzymes are necessaiy for survival, the myelomas will not survive. The unfused normal cells will die because of their limited life span. Thus, after a period of time, the hybridomas will be the only cells left ahve. 

Cytokines. Figure 1 Inhibition of cytokine synthesis during activation of the specific immune system. The monoclonal antibodies Muromonab and Basiliximab are specific for the CD3 complex of the T-cell receptor, and for the IL-2 receptor on lymphocytes, respectively. Cyclosporin and Tacrolimus inhibit activation of cytoplasmic NF-AT, a transcription factor essential for activation of the IL-2 gene ( NFAT Family of Transcription Factors). Sirolimus interferes with mTOR signaling and inhibits IL-2 dependent proliferation. Red pharmaka, blue target proteins. 

A domino RCM of an ene-yne was also used by Granja and coworkers [250] for their synthesis of the B-bishomo-steroid analogue 6/3-70. Reaction of the substrate 6/3-69 with the ruthenium catalyst 6/3-13 led to 6/3-70 in 48% yield as a 6.5 l-mix-ture of the two C-10-epimers (Scheme 6/3.20). The aim of this study was to prepare haptenes for the production of catalytic monoclonal antibodies that could be used to study the mechanism of the physiologically important transformation of previtamin D3 into vitamin D3 [251]. 

R. Roy, M.-G. Baek, and K. Rittenhouse-Olson, Synthesis of /V,/V -bis(acryla-mido)acetic acid base-T antigen glycodendrimers and their mouse monoclonal IgG antibody binding properties, J. Am. Chem. Soc., 123 (2001) 1809-1816. 

Somehow, Seebach ends his superb review, in which more than 500 references are quoted, with a rather optimistic message "that organic synthesis continues to react forcefully and with vitality to new challenges, still ready to pursue old dreams", and he refers to some exciting new targets such as supramolecular structures inhibitors, suicidal substrates and flustrates monoclonal antibodies and... 

It should be pointed out that, in contrast with the enzymes of primary metabolism (e.g., photosynthesis, respiration, etc.), those catalyzing the synthesis of secondary metabolites usually occur in very low abundance, and are therefore, very difficult to purify to homogeneity especially for the purpose of raising antibodies. However, the recent advances in immunization and selection techniques made it possible to overcome the need for homogeneous protein in order to raise monoclonal antibodies. 

G. Vaidyanathan, M.R. Zalutsky, Improved synthesis of N-succinimidyl 4-[ F]fluor-obenzoate and its application to the labeling of monoclonal antibody fragment, Bioconj. Chem. 5 (1994) 352-356. 

---